Hot Deals:
a v thomas 11,770.00 (-0.25 %) adtech 29.00 (-3.33 %) amol minechem 620.00 (1.64 %) anand i-power 20.00 anglo french 370.00 (-2.37 %) aricent 575.00 (0.88 %) arkfin investments 50.00 arohan 181.00 (0.56 %) assam carbon 227.00 (-1.30 %) associated pigments 42.00 (-4.55 %) atlas copco 9,100.00 (1.11 %) auckland international 130.00 (-3.70 %) axles 162.00 (1.25 %) balmer lawrie 300.00 bharat hotels 162.00 (1.25 %) bima mandi 700.00 bira 91 750.00 (-2.85 %) boat 829.00 (-0.12 %) c & s electric 470.00 (-4.08 %) capgemini 12,100.00 (1.68 %) care health 135.00 (3.85 %) carrier aircon 260.00 (1.96 %) cial 180.00 (-1.64 %) csfbl 265.00 (-3.64 %) csk 170.00 (6.25 %) dalmia refract 81.00 (-4.71 %) dsp merrill lynch 1,000.00 east india pharma 44.00 (2.33 %) eaton fluid 380.00 (1.33 %) electronica plastic 4,100.00 (-4.65 %) elgi ultra 400.00 elofic 1,909.00 (0.47 %) esl steel 39.00 (11.43 %) fincare business 43.00 fincare sfbl 74.00 (1.37 %) fino paytech 160.00 (14.29 %) frick india 3,806.00 (0.16 %) gkn drive 1,240.00 (-0.80 %) go digit gil 354.00 (1.14 %) godavari bio 71.00 (1.43 %) hdbfsl 590.00 (-1.67 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,200.00 (-2.61 %) hella india 350.00 (6.06 %) hero fincorp 690.00 (-3.36 %) hicks 2,100.00 (-2.55 %) hira ferro 120.00 (-0.83 %) honeywell electrical 3,555.00 (-1.25 %) icex 5.00 (-0.20 %) incred financial 100.00 india carbon 1,010.00 (1.00 %) india exposition 146.00 (0.69 %) indian potash 1,405.00 (0.36 %) indofil 690.00 (-2.82 %) infinite computer 700.00 inkel 12.95 (-0.38 %) ixigo 97.00 (-2.02 %) jana sfbl 75.00 kial 107.00 (-2.73 %) kurlon enterprise 640.00 (-3.03 %) kurlon limited 426.00 (-3.18 %) lava 127.00 (0.79 %) manipal hfsl 72.50 (0.69 %) manjushree tech 970.00 (-3.10 %) martin & harris 1,500.00 (0.33 %) merino 2,770.00 (0.73 %) minosha 280.00 (-3.45 %) mitsubishi heavy 355.00 (1.43 %) mkcl 415.00 (1.22 %) mobikwik 425.00 (-5.56 %) mohan meakin 1,180.00 (-2.64 %) mohfl 10.75 (-9.66 %) msei 0.98 (-2.00 %) msil 56.00 (3.70 %) nayara energy 152.00 (0.66 %) nayara energy ncd 250.00 ncdex 275.00 ncl buildtek 200.00 (2.56 %) ncl holdings 47.50 (1.06 %) nse 3,050.00 (-1.61 %) orbis financial 86.00 (1.18 %) oswal minerals 65.00 (1.56 %) otis 3,700.00 (-2.63 %) oyo rooms 69.00 (-2.82 %) panasonic appliances 293.00 (-4.25 %) panasonic avc 29.10 (0.34 %) paymate india 600.00 (-3.38 %) pharma easy 32.00 (-8.57 %) philips domestic 605.00 (0.83 %) philips india 1,100.00 (1.85 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 490.00 (-2.00 %) rasoi 32,000.00 (3.23 %) reliance gic 340.00 resins plastics 414.00 (1.97 %) ring plus 370.00 (1.37 %) rrl 2,800.00 (-1.75 %) sab miller 303.00 (1.00 %) satya micro 201.00 (0.50 %) scottish assam 500.00 (-3.85 %) shriram life 251.00 (0.40 %) sigachi lab 40.10 (0.25 %) signify 1,100.00 (4.46 %) simpson & company 3,500,000.00 smile micro 52.00 (-1.89 %) sportskeeda 3,303.00 sterlite power 524.00 (0.19 %) studds 950.00 (-0.52 %) svsml 510.00 (-2.30 %) t stanes 675.00 tata capital 56.00 (1.82 %) tata tech 5,400.00 (4.85 %) teesta agro 67.00 (-4.29 %) trl krosaki 1,224.00 (-2.16 %) utkarsh coreinvest 127.00 (-2.31 %) vikram solar 55.50 (-0.89 %) xerox 243.00 (1.25 %)
×

philips india Limited

1,100.00
+ 1.85 %
Scrip Name
Philips India
ISIN No.
INE319A01016
PAN No.
AABCP9487A
Face Value
10
No. of Outstanding Shares
57,517,242
Market Capitalization
6,326.90 Crore

About PHILIPS INDIA LIMITED Delisted/Unlisted Shares

Philips India Limited is a subsidiary of Royal Philips of the Netherlands, a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment, and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics, as well as in consumer health and home care.                                                                        

INCORPORATION DETAILS

CIN

U31902WB1930PLC006663

Registration Date

31 January 1930

Category/Sub-category of the Company

Company limited by Shares

Address of the Registered office and contact details

3rd Floor, Tower A, DLF IT Park, 08 Block AF, Major Arterial Road, New Town (Rajarhat), Kolkata, West Bengal- 700156.

Name, Address, and Contact Details of

Registrar and Transfer Agent, if any

K fin Technologies Pvt. Ltd, (Formerly “Karvy Fintech Pvt. Ltd.”) Selenium, Tower-B, Plot no.31-32, Gachibowli, Apeejay House, Block “C”, 3rd Floor, Financial District, Nanakramguda, Hyderabad-500 032

BOARD OF DIRECTORS

Chairman and Non-Executive Independent Director - S. M. Datta

Vice-Chairman and Managing Director - Daniel Mazon

Whole-Time Director and Company Secretary - Pooja Bedi

Whole-Time Director and Chief Financial Officer - Sudeep Agrawal

Non-Executive Independent Director -Geetu Gidwani Verma

Shareholders holding more than 5 % shares in the company as on 31 March 2021

Particulars.

As at 31-03-2021

As at 31-03-2020

Koninklijke Philips N.V (KPNV)

 

Number of equity shares

5,52,90,182

5,52,90,182

% of Holding

96.13

96.1

 

SECTORWISE SALES

   

 

2020-21

2019-20

Personal Health

13,459

11,634

Health Systems

19,461

19,055

Innovation Services

14,736

13,860

Others

414

421

Total

48,070

44,970

INDUSTRY OUTLOOK

HEALTH SYSTEMS

During the year 2020-21, the Health Systems business of your Company delivered another year of strong performance irrespective of Market degrowth, driven by growth in Image-Guided Therapy (IGT) (47.6% Market Share) and Connected Care (CC) Business. The Health Systems Equipment Market Share increased by 1.9% at Quarter one of 2020-21 MAT (Moving Annual Turnover) level in the backdrop of macro-economic challenges including low liquidity in Health Care segment due to decline in patient foot-fall in Hospitals and deferment of elective procedures. In Image-Guided Therapy (IGT), Philips Market share improved by 11.2%. The market is still reeling under the stent price capping which is causing the value and performance segments to grow. In Magnetic Resonance (MR), Philips Market share increased by 1.5% fueled by PMRS (circular economy) and improved win rate in government. In Computed Tomography (CT), your Company also showed an increase of 0.5% share. The ultrasound business of your Company improved its market share from 17% to 19.7% driven by the strong performance of India make Affiniti Series launched in the second quarter of 2020. Your Company continues to do strong business with most of its strategic key accounts focusing on multi-modality deals and in government tenders. There are multiple new Product launches such as IGT–Zenition (50 and 70), a new version of Ambition - Helium free magnet and a premium, one of its kind Spectral CT 7500, that would result in your Company gaining further share in a de-growing market, whereas the launch of value patient monitors (GS20) has further strengthened market share for CC business of your company in 2021-22. Your Company’s global innovation strengths at Bangalore (PIC) along with global design and manufacturing at Pune (HIC) are delivering world-class “Made in India” medical equipment. Your Company has implemented a strong strategy for regaining its market share in the next financial year, however, due to the onset of the second wave of COVID-19 pandemic, overall optimism remains subdued.

PERSONAL HEALTH

The financial year 2020-21 was an extraordinary year, wherein the COVID -19 outbreak followed by one of the biggest and unprecedented lockdowns in the world, and its consequent impact on economic, consumer behaviors created both challenges and new opportunities. 23 Annual Report 2020-21 Personal Health businesses continued their transformation journey by adopting to the external dynamic headwinds and delivered 16% growth over the previous financial year. This growth was delivered in a highly competitive environment with low-cost players and challenges as an increase in cost trends of the commodities and adverse currency fluctuations.

 FINANCIALS AT GLANCE

Standalone Balance Sheet as of 31 March 2021 (Amounts in Million) 

 

As at 31-03-2021

As at 31-03-2020

ASSETS

 

 

Non-current assets

 

 

Property, Plant, and Equipment

3,929

3,169

Capital work-in-progress

414

247

Investment property

836

360

Investment in subsidiaries and associates

-

7,431

Financial Assets

 

 

a. Trade Receivables

1,304

938

b. Other Financial Assets

454

486

Deferred tax assets

846

642

Advance income tax (net of

3,122

3,033

Other non-current assets

686

709

 

11,591

17,015

Current assets

 

 

Inventories

4,250

4,169

Contract Assets

380

234

Financial Assets

 

 

a. Trade receivables

5,741

7,943

b. Cash and cash equivalents

9,313

5586

c. Other Financial Assets

186

139

Other current assets

2967

2995

Assets classified as held for sale

14

15

Assets directly associated with discontinued operations

8967

-

TOTAL ASSETS

43409

38096

EQUITY AND LIABILITIES

 

 

EQUITY

 

 

Equity share capital

575

575

Other Equity

23375

22001

Equity attributable to equity shareholders

23950

22576

LIABILITIES

 

 

Non-current liabilities

 

 

Contract Liabilities

906

720

Financial Liabilities

 

 

Lease Liabilities

1584

570

Other non-current liabilities

165

160

Provisions

2435

2945

Total Non-current liabilities

5,090

4,395

Current liabilities

 

 

Contract Liabilities

2282

1894

Financial Liabilities

 

 

Lease Liabilities

721

565

Trade Payables

 

 

Total outstanding dues of micro-enterprises and small enterprises

12

28

Total outstanding dues of creditors other than micro-enterprises and small enterprises

5521

5,847

Other financial liabilities

316

117

Other current liabilities

1670

1537

Provision for taxation (net of

127

208

Provisions

1885

929

Total Current Liabilities

12,534

11,125

Liabilities directly associated with discontinued operations

1835

-

TOTAL EQUITY AND LIABILITIES

43409

38096

 Standalone Statement of Profit and Loss for the year ended 31 March 2021 (Amounts in Million) 

Particulars

2021

2020

Revenue from Operations

48,427

45,342

Other Income

408

422

Total Revenue

48,835

45,764

 change %

6.71%

 

EBITDA

4,126

3,864

EBITDA Margin

8.45%

8.44%

DEP

1,343

1,180

FINANCE COST

252

196

Profit before exceptional items and tax

2,531

2,346

Exceptional items (net) Loss / (Profit)

-

-142

Profit before tax

2,531

2,488

Profit / (loss) from continuing operations

2,396

-

Tax Expense I Current Taxes

-864

-

Deferred tax

113

-

Total Tax Expense - continuing operations

-751

-973

Profit / (loss) from discontinued operations

135

-

Tax expense: Current tax

-43

-

Deferred tax expenses - credit / (charge)

23

-

Profit / (loss) after tax from discontinued operations

115

-

PAT

1,760

1,515

Profit Margin

3.60%

3.31%

 Consolidated Balance Sheet as of 31 March 2021 (Amounts in Million)

Particulars

As at 31-03-2021

As at 31-03-2020

ASSETS

 

 

Non-current assets

 

 

Property, Plant and Equipment

3,929

4,036

Capital work-in-progress

414

247

Investment property

836

59

Goodwill

-

1,191

Financial Assets

 

 

a. Trade Receivables

1,304

938

b. Other Financial Asset

454

517

Deferred tax assets (net)

846

1,774

Advance income tax (net of provision)

3,122

3,065

Other non-current assets

686

736

Total Non-Current Assets

11,591

12,563

Current assets

 

 

Inventories

4,221

4,790

Contract Assets

380

234

Financial Assets

 

 

a. Trade receivables

5,741

8,028

b. Cash and cash equivalents

9,313

8,578

c. Other Financial Assets

186

152

Other current assets

2,968

3,152

Total Current Assets

22,809

24,934

Assets classified as held for sale

14

15

Assets directly associated with discontinued operations

9,650

-

TOTAL ASSETS 

44,064

37,512

EQUITY AND LIABILITIES

 

 

EQUITY

 

 

Equity share capital

575

575

Other Equity

23,345

19,947

Equity attributable to equity shareholders

23,920

20,522

LIABILITIES

 

 

Non-current liabilities

 

 

Contract Liabilities

906

720

Financial Liabilities

 

 

Lease Liabilities

1,584

729

Other non-current liabilities

165

160

Provisions

2,435

3,022

Total Non-Current Liabilities

5,090

4,631

Current liabilities

 

 

Contract Liabilities

2,282

1,903

Financial Liabilities

 

 

Lease Liabilities

721

596

Trade Payables

 

 

(i) Total outstanding dues of micro-enterprises and small enterprises

12

123

(ii) Total outstanding dues of creditors other than micro-enterprises and small enterprises

5,522

6,616

Other financial liabilities

316

126

Other current liabilities

1,670

1,786

Provision for taxation (net of advances)

127

208

Provisions

1,885

1,001

Liabilities directly associated with discontinued operations

2,519

-

Total Current Liabilities

15,054

12,359

TOTAL EQUITY AND LIABILITIES

44,064

37,512

Consolidated Statement of Profit and Loss for the year ended 31 March 2021(Amounts in Million) 

Particulars

 2020-21

 2019-20

Revenue from Operations

55,839

51,945

Other Income

555

589

Total Revenue

56,394

52,534

 change %

7.35%

-

EBITDA

5,128

4,618

EBITDA Margin

9%

9%

DEP

1,440

1,273

FINANCE COST

272

217

Profit before exceptional items and tax

3,416

2,986

Exceptional items (net) Loss / (Profit)

-

-142

Profit before tax

3,416

3,128

Profit / (loss) from continuing operations

2,396

-

Tax Expense I Current Taxes

-864

-877

Deferred tax

113

-814

Total Tax Expense - continuing operations

-751

-1,691

Profit / (loss) after tax from continuing operations

1,645

1,437

Profit / (loss) from discontinued operations

1,018

-

Tax expense: Current tax

-43

-

Deferred tax expenses - credit / (charge)

-173

-

Profit / (loss) after tax from discontinued operations

802

-

PAT

2,447

1,437

Profit Margin

4%

3%

EPS

42.56

24.99

 Dividend History 

Year

2021

2020

Amount

Rs. 3 per Share

Rs. 3 per Share

 PERFORMANCE OF THE COMPANY

The Company has delivered positive net cash from operations in the financial year 2020-21. The company has not made any major borrowings this year and has managed working capital requirements from internal cash generation. During the year, capital expenditure was ` 2,880 million (vis – a – vis ` 967 million during Apr ’19 – Mar ‘20) and was towards the extension of lease agreements in Philips Innovation Campus, vehicles, HIC expansion, IT equipment, etc. Your company continued to facilitate Healthcare sales with innovative financial solutions to support customers and businesses in keeping up pace with the market growth to the tune of ` 1,503 million. The company has invested the surplus cash in fixed deposits with banks and is earning interest on the same.

Wealth Wisdom - WWIPL
Support Megha Support Neha Support Pallavi